2025年,在VOQUEZNA强劲销售的推动下,Phathom制药公司超过了预期收入,提高了2026年的指导意见,同时改善了财务状况。 Phathom Pharmaceuticals exceeded revenue expectations in 2025, driven by strong sales of VOQUEZNA, and raised 2026 guidance while improving its financial position.

Phhothom制药公司报告说,2025年的Q4收入为5 760万美元,粗略估计,2025年全年收入为1.751亿美元,即逐年增长217%,其驱动因素是110多万处方为其药物VOQUEZNA开具了VOQUEZNA。 Phathom Pharmaceuticals reported Q4 2025 revenue of $57.6 million, beating estimates, and full-year 2025 revenue of $175.1 million, a 217% increase year-over-year, driven by over 1.1 million prescriptions for its drug VOQUEZNA. 该公司将2026年的收入指导提高到3.2亿-3.45亿美元,预期从2026年Q3到2026年开始运营的盈利能力不包括基于股票的补偿,2027年的现金流动积极性也不包括基于股票的补偿。 The company raised 2026 revenue guidance to $320–345 million, expects operating profitability excluding stock-based compensation starting in Q3 2026, and cash-flow positivity in 2027. 它通过提供1.3亿美元的股本和债务重组改善了流动性,将其定期贷款减至1.75亿美元,利息较低,到期日延长至2029年。 It improved liquidity through a $130 million equity offering and debt restructuring, reducing its term loan to $175 million with lower interest and extended maturity to 2029. 1 700万至2 000万美元的会计转换将增加报告的收入,但仍保持P & L中立。 A $17–20 million accounting shift will raise reported revenue but remain P&L neutral. 尽管面临近期挑战,但医生的收养和覆盖的处方正在增加,表明胃肠市场具有长期潜力。 Despite near-term challenges, physician adoption and covered prescriptions are growing, signaling long-term potential in the gastrointestinal market.